Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Yourgene Health Plc specializes in genetic testing and diagnostics, particularly in reproductive health and oncology. The company leverages proprietary technologies and partnerships to offer non-invasive prenatal testing (NIPT) and other genomic services primarily in the UK and Europe, positioning itself as a key player in the rapidly growing personalized medicine market.
Yourgene generates revenue through the provision of genetic testing services, with a focus on non-invasive prenatal testing and oncology diagnostics. The company benefits from high gross margins of 56.9%, allowing it to maintain competitive pricing while investing in R&D for new tests and technologies.
Adoption rates of NIPT in the UK and Europe
Regulatory approvals for new genetic tests
Partnership agreements with healthcare providers
Market expansion into Asia-Pacific regions
Regulatory changes affecting genetic testing practices
Technological disruption from competitors offering advanced testing solutions
Emerging competitors in the NIPT space
Price competition from larger diagnostic companies
Negative free cash flow impacting liquidity
Potential reliance on equity financing for growth initiatives
moderate - As a healthcare service provider, demand for genetic testing may be less sensitive to economic cycles, but overall healthcare spending can be influenced by GDP growth.
Interest rates can affect the company's cost of capital and investment in R&D, but the direct impact on demand for genetic testing services is limited.
minimal - Yourgene Health does not rely heavily on credit for operations, given its relatively low debt-to-equity ratio of 0.58.
growth - Investors are likely attracted by the high revenue growth rate and potential for market expansion.
high - The stock has demonstrated significant volatility, evidenced by a 1-year return of -89.2%.